John Woolfrey

EXEL-7647 Inhibits Mutant Forms of ErbB2 Associated with Lapatinib Resistance and Neoplastic Transformation

Torsten Trowe, Sotiria Boukouvala, Keith Calkins et al. · Clinical Cancer Research · 2008 · 133 citations

Medicine, Molecular Biology, Oncology +14

Discovery of betrixaban (PRT054021), N-(5-chloropyridin-2-yl)-2-(4-(N,N-dimethylcarbamimidoyl)benzamido)-5-methoxybenzamide, a highly potent, selective, and orally efficacious factor Xa inhibitor

Penglie Zhang, Wenrong Huang, Lingyan Wang et al. · Bioorganic & Medicinal Chemistry Letters · 2009 · 108 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +7

Structure−Activity Relationships of the Antimalarial Agent Artemisinin. 6. The Development of Predictive In Vitro Potency Models Using CoMFA and HQSAR Methodologies

Mitchell A. Avery, Maria Alvim‐Gaston, Carlos Rangel Rodrigues et al. · Journal of Medicinal Chemistry · 2001 · 85 citations

Pharmacy, Medicinal Chemistry, Pharmacology +16

Discovery of a Novel Class of Highly Potent, Selective, ATP-Competitive, and Orally Bioavailable Inhibitors of the Mammalian Target of Rapamycin (mTOR)

Craig S. Takeuchi, Byung Gyu Kim, Charles M. Blazey et al. · Journal of Medicinal Chemistry · 2013 · 65 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +15

1-(2-Naphthyl)-1 H -pyrazole-5-carboxylamides as potent factor Xa inhibitors. Part 3: Design, synthesis and SAR of orally bioavailable benzamidine-P4 inhibitors

Zhaozhong J. Jia, Yanhong Wu, Wenrong Huang et al. · Bioorganic & Medicinal Chemistry Letters · 2004 · 52 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +8